A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

• Status: Recruiting
• Trial end date: 2027-10-27

Summary

The purpose of this study is to evaluate the efficacy and safety of BMS-986315 plus nivolumab in combination with platinum-based doublet chemotherapy (PDCT) versus nivolumab in combination with PDCT in the first-line treatment of Stage IV or recurrent non-small cell lung cancer (NSCLC).

• Phase: Phase 2

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Carboplatin; Nivolumab; Paclitaxel; Pemetrexed